PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells
MetadataShow full item record
© 2015 Wiley Publishing Asia Pty Ltd. Colon cancer is one of the most common cancers worldwide with high mortality. A major issue in colon cancer treatment is drug-resistance and metastasis that have been ascribed to the cancer stem cells. In this study, colon cancer stem cells were isolated through sphere culture and verified with the cancer stem cell markers CD133, CD44, and CD24. It was demonstrated that the PI3K/Akt/mTOR signalling pathway was highly activated in the colon cancer stem cells and that inhibition of the PI3K/Akt/mTOR pathway by the inhibitor BEZ235 suppressed the colon cancer stem cell proliferation with reduced stemness indicated by CD133 and Lgr5 expressions. Treatment with insulin as a known activator of the PI3K/Akt pathway increased CD133 expression and decreased the effects of BEZ235 on colon cancer proliferation and survival. The data presented here collectively suggest that the PI3K/Akt/mTOR pathway underpins the stemness of colon cancer stem cells and BEZ235 is potentially a good drug candidate for treatment of colon cancer drug resistance and metastasis.
Showing items related by title, author, creator and subject.
TRAIL up-regulation must be accompanied by a reciprocal PKCe down-regulation during differentiation of colonic epithelial cell: Implications for colorectal cancer cell differentiationGobbi, G.; Di Marcantonio, D.; Micheloni, C.; Carubbi, C.; Galli, D.; Vaccarezza, Mauro; Bucci, G.; Vitale, M.; Mirandola, P. (2012)PKC isoenzymes play central roles in various cellular signalling pathways, participating in a variety of protein phosphorylation cascades that regulate/modulate cellular structure and gene expression. It has been firmly ...
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerSerra, V.; Scaltriti, M.; Prudkin, L.; Eichhorn, Pieter ; Ibrahim, Y.H.; Chandarlapaty, S.; Markman, B.; Rodriguez, O.; Guzman, M.; Rodriguez, S.; Gili, M.; Russillo, M.; Parra, J.L.; Singh, S.; Arribas, J.; Rosen, N.; Baselga, J. (2011)There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since it is highly deregulated in this disease ...
Targeting phosphoinositide 3-kinase pathways in pancreatic cancer - from molecular signalling to clinical trialsFalasca, Marco; Selvaggi, F.; Buus, R.; Sulpizio, S.; Edling, C. (2011)Pancreatic cancer has one of the poorest prognoses among all cancers partly because of its silent nature and tendency for late discovery but also because of its persistent resistance to chemotherapy. At present there are ...